References
- BallAJThe natural history of untreated “prostatism”BJU Int198153613616
- JacobsenSJNatural history of prostatism: Longitudinal changes in voiding symptoms in community dwelling menJ Urol19961555956008558668
- ArrighiHMNatural history of benign prostatic hyperplasia and the risk of prostatectomy The Baltimore Longitudinal Study of AgingUrology199138Suppl 1481714657
- RoehrbornCAUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendationsJ Urol200317053054712853821
- RoehrbornCGα1-Adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasiaJ Urol20041711029103514767264
- LeporHPhase III multicenter placebo-controlled study of tamsulaosin in benign prostatic hyperplasia. Tamsulosin Investigator GroupUrol1998518929009609623
- ThompsonIMThe influence of finasteride on the development of prostate cancerN Engl J Med200334921522412824459
- AbromociczMDutasteride (Avodart) for benign prostatic hyperplasiaMed Lett Drug Ther200244109110
- BramsonHNUnique preclinical characteristics of GG745, a potent dual inhibitor of 5ARJ Pharmacol Exp Ther199728219461502
- RoehrbornCGEfficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasiaUrol20026043444112350480
- AVODART (dutasteride): Prescribing informationPhysicians’ Desk Reference58th edMontvale, NJThompson PDR200414561459
- RoehrbornCGLong-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5α-reductase inhibitor dutasteride: results of 4-year studiesBJU Int20059657257716104912
- SchulmanCLong-term therapy with dual 5α-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasiaBJU Int200697737916336332
- O’LearyMPImprovements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5α-reductase inhibitorBJU Int20039226226612887480
- DesgrandchampsFEffect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort in clinical practiceBJU Int200698838816831149
- BostwickDGDoes finasteride alter the pathology of the prostate and cancer gradingClin Prostate Cancer2004222823515072606
- GomellaLGChemoprevention using dutasteride: The Reduce TrialCurr Opin Urol200515293215586026
- MerrickGSEfficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapyUrol20066811612016844453
- NarayanPLong-term efficacy and safety of tamsulosin for benign prostatic hyperplasiaRev Urol20057Supp 4S42S4816986054
- McConnellJDThe long-term effect of doxazosinzocin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasiaN Engl J Med20033492449245114681512
- RoehrbornCGThe effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT studyJ Urol200817961662118082216